Overcoming Platelet-Induced Resistance and Enhancing Anti-Invasive Activity

Background:A phase I/II clinical trial in advanced hepatocellular carcinoma (HCC) conducted by Yakult Honsha (NCT02400788) indicated the combination of the HDAC inhibitor resminostat and sorafenib was beneficial compared to sorafenib for patients wit...